Imetelstat
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Imetelstat
- DrugBank Accession Number
- DB14909
- Background
Imetelstat is under investigation in clinical trial NCT01916187 (Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 4610.18
Monoisotopic: 4606.886420162 - Chemical Formula
- C148H211N68O53P13S13
- Synonyms
- Imetelstat
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- F60NE4XB53
- CAS number
- 868169-64-6
- InChI Key
- LVZYXEALRXBLJZ-UHFFFAOYSA-N
- InChI
- InChI=1S/C148H211N68O53P13S13/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-97(218)160-34-69(217)38-255-282(242,295)256-51-95-74(25-102(261-95)207-37-68(4)136(221)191-148(207)229)195-274(234,287)249-45-89-78(29-106(264-89)212-61-175-115-124(155)165-56-170-129(115)212)199-277(237,290)252-48-92-81(32-109(267-92)215-64-178-118-132(215)183-143(158)187-139(118)224)202-280(240,293)254-50-94-82(33-110(269-94)216-65-179-119-133(216)184-144(159)188-140(119)225)203-281(241,294)253-49-93-79(30-107(268-93)213-62-176-116-130(213)181-141(156)185-137(116)222)200-278(238,291)246-42-86-72(23-100(260-86)205-35-66(2)134(219)189-146(205)227)193-272(232,285)245-41-85-73(24-101(259-85)206-36-67(3)135(220)190-147(206)228)194-273(233,286)248-44-88-77(28-105(263-88)211-60-174-114-123(154)164-55-169-128(114)211)198-276(236,289)251-47-91-80(31-108(266-91)214-63-177-117-131(214)182-142(157)186-138(117)223)201-279(239,292)250-46-90-76(27-104(265-90)210-59-173-113-122(153)163-54-168-127(113)210)197-275(235,288)244-40-84-71(22-99(258-84)204-20-19-96(150)180-145(204)226)192-271(231,284)247-43-87-75(26-103(262-87)209-58-172-112-121(152)162-53-167-126(112)209)196-270(230,283)243-39-83-70(149)21-98(257-83)208-57-171-111-120(151)161-52-166-125(111)208/h19-20,35-37,52-65,69-95,98-110,217H,5-18,21-34,38-51,149H2,1-4H3,(H,160,218)(H,242,295)(H2,150,180,226)(H2,151,161,166)(H2,152,162,167)(H2,153,163,168)(H2,154,164,169)(H2,155,165,170)(H,189,219,227)(H,190,220,228)(H,191,221,229)(H2,192,231,284)(H2,193,232,285)(H2,194,233,286)(H2,195,234,287)(H2,196,230,283)(H2,197,235,288)(H2,198,236,289)(H2,199,237,290)(H2,200,238,291)(H2,201,239,292)(H2,202,240,293)(H2,203,241,294)(H3,156,181,185,222)(H3,157,182,186,223)(H3,158,183,187,224)(H3,159,184,188,225)
- IUPAC Name
- [(2S,3S,5R)-3-[({[(2S,3S,5R)-3-[({[(2S,3S,5R)-3-[({[(2S,3S,5R)-3-[({[(2S,3S,5R)-3-[({[(2S,3S,5R)-3-[({[(2S,3S,5R)-3-[({[(2S,3S,5R)-3-[({[(2S,3S,5R)-3-[({[(2S,3S,5R)-3-[({[(2S,3S,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-[({[(2S,3S,5R)-3-[({[(2S,3S,5R)-3-amino-5-(6-amino-9H-purin-9-yl)oxolan-2-yl]methoxy}(sulfanyl)phosphoryl)amino]-5-(6-amino-9H-purin-9-yl)oxolan-2-yl]methoxy}(sulfanyl)phosphoryl)amino]oxolan-2-yl]methoxy}(sulfanyl)phosphoryl)amino]-5-(6-amino-9H-purin-9-yl)oxolan-2-yl]methoxy}(sulfanyl)phosphoryl)amino]-5-(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)oxolan-2-yl]methoxy}(sulfanyl)phosphoryl)amino]-5-(6-amino-9H-purin-9-yl)oxolan-2-yl]methoxy}(sulfanyl)phosphoryl)amino]-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-2-yl]methoxy}(sulfanyl)phosphoryl)amino]-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-2-yl]methoxy}(sulfanyl)phosphoryl)amino]-5-(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)oxolan-2-yl]methoxy}(sulfanyl)phosphoryl)amino]-5-(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)oxolan-2-yl]methoxy}(sulfanyl)phosphoryl)amino]-5-(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)oxolan-2-yl]methoxy}(sulfanyl)phosphoryl)amino]-5-(6-amino-9H-purin-9-yl)oxolan-2-yl]methoxy}(sulfanyl)phosphoryl)amino]-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-2-yl]methyl 3-hexadecanamido-2-hydroxypropyl sulfanylphosphonate
- SMILES
- CCCCCCCCCCCCCCCC(=O)NCC(O)COP(S)(=O)OCC1OC(CC1NP(S)(=O)OCC1OC(CC1NP(S)(=O)OCC1OC(CC1NP(S)(=O)OCC1OC(CC1NP(S)(=O)OCC1OC(CC1NP(S)(=O)OCC1OC(CC1NP(S)(=O)OCC1OC(CC1NP(S)(=O)OCC1OC(CC1NP(S)(=O)OCC1OC(CC1NP(S)(=O)OCC1OC(CC1NP(S)(=O)OCC1OC(CC1NP(S)(=O)OCC1OC(CC1NP(S)(=O)OCC1OC(CC1N)N1C=NC2=C1N=CN=C2N)N1C=NC2=C1N=CN=C2N)N1C=CC(N)=NC1=O)N1C=NC2=C1N=CN=C2N)N1C=NC2=C1N=C(N)NC2=O)N1C=NC2=C1N=CN=C2N)N1C=C(C)C(=O)NC1=O)N1C=C(C)C(=O)NC1=O)N1C=NC2=C1N=C(N)NC2=O)N1C=NC2=C1N=C(N)NC2=O)N1C=NC2=C1N=C(N)NC2=O)N1C=NC2=C1N=CN=C2N)N1C=C(C)C(=O)NC1=O
References
- General References
- Not Available
- External Links
- Wikipedia
- Geron_Corporation
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Recruiting Treatment Myelofibrosis 1 2 Completed Treatment Essential Thrombocythemia (ET) / Polycythemia Vera (PV) 1 2 Completed Treatment Multiple Myeloma (MM) 1 2 Completed Treatment Myelofibrosis 1 2 Completed Treatment Myeloid Malignancies / Primary Myelofibrosis (PMF) / Secondary Myelofibrosis 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -3.2 Chemaxon pKa (Strongest Acidic) 0.29 Chemaxon Physiological Charge -12 Chemaxon Hydrogen Acceptor Count 74 Chemaxon Hydrogen Donor Count 45 Chemaxon Polar Surface Area 1587.05 Å2 Chemaxon Rotatable Bond Count 95 Chemaxon Refractivity 1045.35 m3·mol-1 Chemaxon Polarizability 442.86 Å3 Chemaxon Number of Rings 35 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at May 20, 2019 14:34 / Updated at February 21, 2021 18:55